JHL Biotech names Dr Rong Chen as new CMO.
M2 EQUITYBITES-January 2, 2018-JHL Biotech names Dr Rong Chen as new CMO
(C)2018 M2 COMMUNICATIONS http://www.m2.com
JHL Biotech Inc (Taipei:6540), a biopharmaceutical start-up, announced on Monday the appointment of Dr Rong Chen as chief medical officer, effective 1 January 2018.
In his new role, Dr. Chen will oversee JHL's medical and clinical development work as part of its mission to make world-class biopharmaceuticals affordable and available to more patients.
Most recently, Dr Chen was chief medical officer at Phagelux, a biologics company in Shanghai. Prior to Phagelux, he was CMO at CASI Pharmaceuticals, VP and head of Regulatory Excellence for China/HK area at GlaxoSmithKline, medical director for the Asia Pacific region at Beyer Schering Pharma and medical director for China at Sanofi.
Earlier, Dr Chen has held several clinical and research positions in Australia.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jan 2, 2018|
|Previous Article:||ZK International closes offering of 86,666 for USD520,000.|
|Next Article:||Hilton announces new Hilton Huizhou Longmen Resort in China.|